NovoCure (NVCR) Net Cash Flow (QoQ) (2015 - 2026)
NovoCure (NVCR) Net Cash Flow (QoQ) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | NovoCure | 2.06 Bn | 1.62 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 206.17% |
| Mar 31, 2026 | 97.54% |
| Dec 31, 2025 | -225.27% |
| Sep 30, 2025 | 758.08% |
| Jun 30, 2025 | 160.82% |
| Mar 31, 2025 | -60.55% |
| Dec 31, 2024 | -211.17% |
| Sep 30, 2024 | 107.16% |
| Jun 30, 2024 | -234.44% |
| Mar 31, 2024 | 150.26% |
| Dec 31, 2023 | 9,800.79% |
| Sep 30, 2023 | 96.96% |
| Jun 30, 2023 | -141.17% |
| Mar 31, 2023 | 155.13% |
| Dec 31, 2022 | -3.83% |
| Sep 30, 2022 | -170.14% |
| Jun 30, 2022 | 1,081.59% |
| Mar 31, 2022 | 96.27% |
| Dec 31, 2021 | -245.71% |
| Sep 30, 2021 | 853.80% |